5.980SEK-1.48%Mkt Cap: 361.57M SEKP/E: —Last update: 2026-05-13
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical tri…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-12.04
PEG—
P/B0.62
P/S—
EV/EBITDA-2.54
EV/Revenue—
EPS (TTM)-2.17
EPS (Forward)-0.49
Cash Flow & Leverage
FCF Yield-12.19%
FCF Margin—
Operating CF-81.53M SEK
CapEx (TTM)307.00K SEK
Net Debt/EBITDA0.43
Net Debt-45.81M SEK
Technical
SMA 504.754 (+25.8%)
SMA 2005.718 (+4.6%)
Beta0.71
S&P 52W Chg24.23%
Avg Vol (30d)33.01K
Avg Vol (10d)68.97K
Technical Indicators
RSI (14)63.1
MACD0.2701
MACD Signal0.1608
MACD Hist.+0.1093
BB Upper6.078 SEK
BB Middle5.161 SEK
BB Lower4.245 SEK
BB Width35.52%
ATR (14)0.6112 SEK
Vol Ratio (20d)0.91x
52W Range
3.86030% of range10.98
52W High10.98 SEK
52W Low3.860 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-19.36%
ROA-18.03%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.03
Current Ratio2.69
Quick Ratio2.47
Book Value/Sh9.537 SEK
Cash/Share1.054 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 3, 2024
Ownership
Shares Out.61.28M
Float20.69M
Insiders67.21%
Institutions13.22%
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)16.00 SEK
Target Range16.00 SEK – 16.00 SEK
# Analysts1
Company
Market Cap361.57M SEK
Enterprise Value269.53M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-113.26M SEK
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees27
Last Price5.980 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—